The ARHGEF2 Knockout HEK293T Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population designed for loss-of-function studies of the ARHGEF2 gene (also known as GEF-H1) in a widely used human embryonic kidney cell background. This product is generated by CRISPR/Cas9-mediated gene disruption, yielding a heterogeneous pool of edited cells that collectively ablate functional ARHGEF2 protein expression, providing a robust model for investigating the cellular consequences of ARHGEF2 depletion without clonal selection artifacts.
The host cell line, HEK293T, is a derivative of the HEK293 line that stably expresses the SV40 large T antigen. This genetic modification permits episomal replication of plasmids carrying the SV40 origin of replication, leading to high-level recombinant protein production and efficient retroviral/lentiviral packaging. HEK293T cells are a standard workhorse in biomedical research, widely applied in transient gene expression, viral vector production, and gene editing experiments due to their high transfectability and reliable growth characteristics.
At the molecular level, ARHGEF2 encodes a microtubule-associated guanine nucleotide exchange factor that serves as a critical activator of the small GTPases RhoA and Rac1. Sequestered on microtubules in its inactive state, ARHGEF2 is released upon microtubule depolymerization or specific upstream signals, including phosphorylation by PAK1 and ERK, as well as mechanical cues from integrin-mediated cell-ECM adhesion. Once liberated, it catalyzes GDP/GTP exchange on RhoA and Rac1, triggering downstream effectors such as ROCK, LIMK, and Cofilin to reorganize the actin cytoskeleton. This cascade promotes stress fiber formation, focal adhesion maturation via FAK and SRC kinases, and cell contractility, while also modulating transcription factors like SRF and stress-responsive JNK pathways. Key interaction partners include tubulin, 14-3-3 proteins, Par3, and cingulin, positioning ARHGEF2 at a nexus between microtubule dynamics and actin-adhesion networks.
In the HEK293T context, the ARHGEF2 knockout polyclonal cells offer a unique tool to dissect Rho GTPase signaling and cytoskeletal regulation in an experimentally tractable system. The knockout background enables direct assessment of ARHGEF2-dependent phenotypes, such as altered cell spreading, migration, or adhesion dynamics, which can be further complemented by rescue experiments using transiently expressed wild-type or mutant ARHGEF2. Given the host cells?? proficiency in protein production, this model is especially suited for biochemical assays that require high-level expression of signaling components, and its compatibility with viral packaging facilitates the generation of downstream functional reporters.
Researchers can employ these cells in a diverse array of applications, including cancer cell migration and invasion studies using Transwell or wound-healing assays, quantitative analysis of RhoA and Rac1 activation via GST pull-down, and immunofluorescence microscopy to visualize actin stress fiber and microtubule network alterations. Additionally, the cells are ideal for investigating ARHGEF2??s role in drug response for metastasis, performing co-immunoprecipitation to map protein interaction networks, and analyzing gene expression changes by quantitative PCR of downstream targets such as SRF-mediated transcripts. For complete details on handling, culture conditions, and genetic validation, please contact Ascent Research.
